Quick Answer
Barinthus Biotherapeutics plc. reported Cash and Equivalents of $70.46 million for fiscal year 2025.
Barinthus Biotherapeutics plc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $70.46M | -36.3% |
| 2024 | $110.66M | -22.1% |
| 2023 | $142.09M | -26.9% |
| 2022 | $194.38M | -9.2% |
| 2021 | $214.05M | +394.7% |
| 2020 | $43.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $74.27M | — | -13.9% |
| June 30, 2025 | $86.26M | — | -13.0% |
| March 31, 2025 | $99.12M | — | -10.4% |
| December 31, 2024 | $110.66M | — | -31.0% |
| September 30, 2023 | $160.31M | -19.9% | -7.4% |
| June 30, 2023 | $173.03M | -10.0% | -9.6% |
| March 31, 2023 | $191.33M | -4.6% | -1.6% |
| December 31, 2022 | $194.38M | -9.2% | -2.9% |
- Barinthus Biotherapeutics plc. showed a decrease of -36.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Barinthus Biotherapeutics plc.’s cash and equivalents has grown by 62.8% (from $43.27 million to $70.46 million).
- The most recent figure is from Barinthus Biotherapeutics plc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: